Inclusion Criteria:

          1. The patient willing to give written signed and dated informed consent to participate
             in the study.

          2. Patient must have histopathologically or cytologically confirmed triple negative
             breast cancer.

          3. Patients may have received one prior chemotherapy regimen for adjuvant therapy and/or
             one chemotherapy treatment/regimen for firstline metastatic therapy

          4. Patients with locally advanced or metastatic breast cancer after failure of prior
             chemotherapy.

          5. Have at least one measurable lesion as per the RECIST criteria (version 1.1).

          6. Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to two

          7. Left Ventricular Ejection fraction (LVEF) greater than or equal to 50 percentage as
             per Echocardiography (ECHO).

          8. Patient must have recovered from any toxic effects of previous chemotherapy or
             radiotherapy as judged by the Investigator.

          9. Previous chemotherapy or radiotherapy should be completed 4 weeks prior to start of
             IMP administration.

         10. Patients with life expectancy of at least 6 months.

         11. Serum pregnancy test at screening and urine pregnancy test on Day 1 (before
             randomization) must be negative.

         12. Sexually active women, unless surgically sterile or postmenopausal for at least 12
             consecutive months, must use an effective method of avoiding pregnancy (including
             oral, transdermal, or implanted contraceptives [any hormonal method in conjunction
             with a secondary method], intrauterine device, female condom with spermicide,
             diaphragm with spermicide, absolute sexual abstinence, use of condom with spermicide
             by sexual partner or sterile [at least 6 months prior to Study drug administration]
             sexual partner) for at least four weeks prior to study drug administration, during
             study and up to 30 days after the last dose of study drug. Cessation of birth control
             after this point should be discussed with a responsible physician.

         13. Patient with adequate bone marrow, renal and hepatic function.

        Exclusion Criteria:

          1. Patient who has a history of hypersensitivity reactions to Docetaxel or any other
             component of formulation or to any drugs formulated with polysorbate 80.

          2. Patients with a history of HER2 positive over expression and hormone receptor positive
             (ER or PR)

          3. Patient who is already exposed to Docetaxel injection in metastatic setting.

          4. Any of the cardiac conditions like Unstable angina, Myocardial infarction within the
             past six months, Severe uncontrolled ventricular arrhythmias, Clinically significant
             pericardial disease, Electrocardiographic evidence of acute ischemia, Patient with
             evidence of abnormal cardiac conduction (e.g., bundle branch block or heart block)
             except in whom the disease has been stable for the past six months, History of cardiac
             disease that met the NYHA Classification class 2 or greater

          5. Uncontrolled diabetes or infection.

          6. Known history of drug addiction within last one year.

          7. Patients with known CNS lesions (brain metastasis or carcinomatous meningitis) except
             for asymptomatic brain metastases.

          8. The receipt of an investigational medicinal product or participation in other drug
             research study within a period of 30 days prior to the first dose of investigational
             medicinal Product for the current study.

          9. Pre-existing motor or sensory neurotoxicity of a severity greater than or equal to
             grade two as defined by NCI CTCAE 4.03 criteria.

         10. Known case of HIV infection.

         11. Any other condition that, in the investigator's judgment, might increase the risk to
             the patient or decrease the chance of obtaining satisfactory data needed to achieve
             the objectives of the study.

         12. Patients who are unwilling or unable to follow protocol requirements